Li Zhenping's 350 Million Yuan and Bluefish Medical's "Breaking Point" Moment

Question AI · Does the sale of Wuhan Bikaier mean a shift in Blue Sail Medical’s strategic focus?

This newspaper (chinatimes.net.cn) reporter Zhao Wenjuan and Na Beijing report

On March 16, Blue Sail Medical issued an announcement. The company’s actual controller, Li Zhenping, plans to lend 350 million yuan to the listed company for one year to optimize capital and debt structure.

This is not Li Zhenping’s first move. Just a few days ago, Blue Sail Medical disclosed two acquisitions—spending 800 million yuan to integrate the capacity of its subsidiary nitrile glove production, and spending 400 million yuan to buy an 80% stake in a thermal power company from the actual controller. On one hand, the actual controller is lending money to the company; on the other, the company is spending money to buy assets from the actual controller. Between borrowing and buying, Blue Sail Medical’s situation becomes clear: this glove industry leader, which has been losing money for four consecutive years, is undergoing a process of internal “self-rescue.”

In response to this issue, Huaxia Times reporter attempted to contact Blue Sail Medical for an interview but had not received a reply as of press time.

Money on the books and maturing debts

Let’s look at some figures.

The 2025 performance forecast shows that Blue Sail Medical’s net profit attributable to the parent will lose between 650 million and 850 million yuan, with a non-recurring profit and loss loss of 780 million to 980 million yuan. Compared to the 446 million yuan loss in 2024, the loss not only did not narrow but further expanded.

(Screenshot from the 2025 performance forecast)

The direct consequence of continuous losses is the ongoing depletion of on-hand funds. As of the third quarter of 2025, the company’s cash and cash equivalents amounted to only 1.357 billion yuan, and including trading financial assets, total cash assets were only 2.2 billion yuan. Meanwhile, short-term debt has exceeded 4.4 billion yuan.

The debt structure is also not optimistic. The 1.52 billion yuan convertible bonds will mature in two months, with high foreign currency borrowings pressing down, plus a 1 billion yuan hedging repurchase obligation hanging overhead. The item “non-current liabilities due within one year” jumped from 1.283 billion yuan at the end of Q1 to 4.025 billion yuan at the end of Q3. The current ratio is 0.9, and the quick ratio is 0.7—both falling below warning levels—making debt repayment pressure a looming sword.

(Screenshot from Wind)

Against this backdrop, on March 17, the conversion price of the “Blue Sail Convertible Bond” was lowered to 7.95 yuan per share, marking the eighth reduction since 2024. However, the room for further reduction is extremely limited. According to regulations, the conversion price cannot be lower than the latest audited net asset per share, which was 7.65 yuan in the third quarter of 2025.

Since March, Blue Sail Medical’s stock price has risen from around 6 yuan to about 8 yuan, but the conversion progress has not significantly improved. With only two months left until the maturity of the convertible bonds, the 1.52 billion yuan repayment pressure is unavoidable.

In addition, Blue Sail Medical faces a large tax payment pressure in 2025. The company announced that, according to tax authorities, a special tax adjustment self-inspection was conducted on cross-border related-party transactions of the health protection division from 2020 to 2022. By December 31, 2025, the company and its subsidiaries are expected to pay additional taxes and interest totaling 196 million yuan. After deducting pre-paid and withheld amounts, the remaining 141 million yuan will be recorded as current profit and loss for 2025. For Blue Sail Medical, burdened with over 4 billion yuan in short-term debt, this large tax payment undoubtedly worsens its cash flow pressure.

Under multiple pressures, the company has listed a series of measures: introducing strategic investors, disposing of some assets, issuing new debt… Among these, the most immediate and painful step is to sell Wuhan Bikaier—the “hidden champion” that has achieved the world’s leading capacity in the global first aid kit market.

On March 13, 2026, during investor relations activities, the company explicitly stated that it would realize further focus on its two main businesses—health protection and cardiovascular and cerebrovascular sectors—through asset sales.

This means that the business segment once expected to be a key growth driver is now being divested from Blue Sail Medical’s strategic map.

From “spin-off listing” to “painful sacrifice”

The story of Wuhan Bikaier was once very promising.

In 2020, Blue Sail Medical entered the first aid kit export market through the acquisition of Wuhan Bikaier. That was the company’s peak moment— in that year, PVC glove prices surged, and Blue Sail Medical’s net profit attributable to the parent reached 1.758 billion yuan, a 2.5-fold increase year-on-year.

After the acquisition, Blue Sail Medical continued to expand. In November 2022, the company invested 800 million yuan in Huanggang, Hubei, to build an annual capacity of 10 million first aid kits. The plan was ambitious: to reach an annual sales of 2 billion yuan within 3-5 years and achieve a split listing under Blue Sail.

The investment indeed brought scale. To date, the capacity of first aid kits has reached 20 million sets per year, ranking first globally, and the emergency rescue division has become an absolute leader in this niche market. In July 2025, Blue Sail Emergency Technology (Wuhan) Co., Ltd. was officially established, aiming to develop the domestic emergency rescue market. At that time, the market was generally optimistic about this sector’s prospects.

However, just five months later, an abrupt reversal occurred.

On December 31, 2025, Mindray Bio announced its plan to acquire 100% equity of Wuhan Bikaier with cash. The transaction was expected to constitute a major asset restructuring. In February 2026, Blue Sail Medical officially confirmed this strategic adjustment during investor relations activities.

From the ambition of a spin-off listing to the reality of a full sale, only three years have passed.

The market was not surprised by this sale. By then, Blue Sail Medical had been losing money for four consecutive years: a loss of 372 million yuan in 2022, 568 million yuan in 2023, 446 million yuan in 2024, and an estimated loss of 650-850 million yuan in 2025. Behind these losses are sluggish core businesses and multiple pressures—tax payments, fixed asset impairments, valuation fluctuations of investment projects, and financial costs from past financing—all draining the already tight cash flow.

Tax payments are particularly tricky. The immediate cash outflow of 141 million yuan is like adding salt to the wound for a company burdened with over 4 billion yuan in short-term debt, further tightening liquidity.

Selling Wuhan Bikaier is a way to stop bleeding but also a drastic measure. Compared to the impending maturity of the hedging agreement, it might just be “appetizer.”

Countdown to the hedging agreement

Beyond asset sales, Blue Sail Medical faces an even more urgent issue: Blue Sail Box.

In 2024, its subsidiary Beijing Blue Sail Box Medical Technology Co., Ltd. introduced a strategic investment of 1 billion yuan. The Series A1 round involved a total of 900 million yuan from the Capital Health Industry Fund, the Kongkong Private Equity Fund, and the High-tech Industry Investment, acquiring 18.37% equity; simultaneously, Blue Sail Medical converted its debt into equity in Blue Sail Box, with a post-investment valuation of 5.5 to 5.7 billion yuan. The Series A2 round brought in the Daxing Kongkong Development Fund, investing 10 million yuan at a pre-money valuation of 4.9 billion yuan, raising the post-investment valuation to 5.6-5.8 billion yuan.

At the time, this financing was called “the second-largest private equity financing transaction in China’s medical device field in recent two years.”

But behind this glamorous financing was a binding hedging agreement: Blue Sail Box needed to go public before September 30, 2026. If not, investors could require Blue Sail Medical to buy back shares and pay an annualized return of 10%.

Now, with just over half a year left until the deadline, Blue Sail Box’s listing progress has not made substantial headway. Since the potential buyback obligation is recognized as a financial liability at the consolidation level, Blue Sail Medical continued to accrue 100 million yuan in financial expenses in 2025. Although this does not involve cash outflow, it results in real losses on the financial statements.

While the countdown to the hedging agreement continues, another crisis looms: the 1.52 billion yuan convertible bonds will mature in two months. At this moment, Li Zhenping’s 350 million yuan loan has been received.

Can this money solve the problem?

Tax expert Liu Zhigeng told Huaxia Times that this loan, while not solving the fundamental issues, has a clear strategic intent: “In the short term, it alleviates public opinion pressure and signals the actual controller’s backing. This interest-free or low-interest loan from the actual controller, which requires no collateral, is essentially a low-cost trust endorsement, helping to stabilize creditors, investors, and suppliers’ sentiment to avoid runs or credit chain breaks. In the medium term, it works with the reduction of the conversion price to buy time for conversion. The most urgent risk for Blue Sail Medical now is the 1.52 billion yuan convertible bonds maturing in May 2026. If the stock price remains depressed and conversion cannot be promoted, the company will face huge cash repayment pressure. In the long term, it aims to buy time for strategic adjustment: focusing on cardiovascular and cerebrovascular sectors. Blue Sail Medical is pushing forward a major strategic transformation: focusing on cardiovascular and health protection, and divesting non-core assets like emergency rescue. This loan is essentially buying precious breathing room for this ‘business slimming + structural optimization’ transformation, avoiding forced sale of quality assets due to short-term liquidity shortages.”

But a temporary check cannot fill the over 4 billion yuan short-term debt gap, nor change the fundamental problem of four years of losses, nor pause the countdown of the hedging agreement. Selling Wuhan Bikaier can bring cash, but it also means cutting off a once globally leading business segment.

“Blue Sail Medical currently faces three interconnected problems: tax payments worsen losses, losses worsen liquidity, and liquidity crises force asset sales and shareholder injections. The actual controller’s loan is a ‘band-aid’ measure; divesting emergency rescue is a ‘cutting flesh’ move; tax issues are the long-term aftermath of reckless growth. Whether the company can survive depends on whether its core businesses—health protection and cardiovascular—can quickly turn losses around, and whether debt restructuring can proceed smoothly,” said Bai Wenxi, Vice Chairman of the China Enterprise Capital Alliance, to our reporter.

Looking at the two main businesses, the health protection sector was once Blue Sail Medical’s profit pillar but fell into losses in 2025 due to international trade policy fluctuations and intensified industry competition. The good news is that in 2025, the cardiovascular division achieved an annual revenue of 1.4 billion yuan, with a growth rate of over 24%, and even turned profitable despite fair value adjustments of invested companies (pre-IPO financing of Tongxin Medical caused a 120 million yuan fair value loss).

What Blue Sail Medical is experiencing is not an active transformation but a passive self-rescue. The final outcome of this self-rescue depends on three variables: how much ‘ammunition’ can be gained from selling Bikaier, whether Blue Sail Box can beat the half-year listing deadline, and when the sluggish glove market will recover.

Editor: Jiang Yuqing Chief Editor: Chen Yanpeng